Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Novel CD8+ T cell antagonists based on beta 2-microglobulin.

Meir Glick1, David A Price, Anne-Lise Vuidepot

  • 1Department of Chemistry, Central Chemistry Laboratory, University of Oxford, South Parks Road, Oxford, United Kingdom.

The Journal of Biological Chemistry
|March 27, 2002
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

New insights into progenitor exhausted T cell populations.

Nature reviews. Immunology·2026
Same author

CD8 T Cell Sensing of Type I Interferon Impacts Anergy.

European journal of immunology·2026
Same author

A probiotic bacterium modulates antitumour γδ T-cell responses in lung cancer.

Frontiers in immunology·2026
Same author

Increased Constitutive Interferon-β Levels and Altered CD4 T Cell Homeostasis Induced by Expression of a Viral Glycoprotein.

European journal of immunology·2026
Same author

Position-5-driven reorientation of an immunodominant HLA-A*24:02 SARS-CoV-2 epitope drives universal T cell escape.

JCI insight·2026
Same author

Protocol for MR1-ligand cross-linking to discover metabolite antigens by proteomics.

STAR protocols·2026

Mutation of beta(2)-microglobulin in MHC class I molecules dramatically impacts CD8alphaalpha binding and cytotoxic T lymphocyte (CTL) activation. A specific mutation enhances MHC interactions but reduces CD8 binding, offering a novel immunosuppression strategy.

Area of Science:

  • Immunology
  • Molecular Biology
  • Biochemistry

Background:

  • The CD8 coreceptor on cytotoxic T lymphocytes (CTLs) binds to Major Histocompatibility Complex (MHC) class I molecules, a critical step for CTL activation.
  • Beta(2)-microglobulin (B2M), the light chain of MHC class I, contributes to CD8alphaalpha binding, primarily via Lysine 58.

Purpose of the Study:

  • To investigate the effect of B2M mutations on CD8alphaalpha binding and CTL activation.
  • To explore the potential of modulating B2M interactions for therapeutic immunosuppression.

Main Methods:

  • Molecular modeling to predict the impact of B2M mutations.
  • Surface plasmon resonance (SPR) binding studies to quantify binding affinities.
  • Human CTL activation assays to assess functional consequences.

Related Experiment Videos

Main Results:

  • Molecular modeling predicted a significant impact of B2M mutations on CD8alphaalpha binding.
  • SPR and CTL assays confirmed that the Lys58 mutation dramatically alters CD8alphaalpha binding.
  • The charge-reversing mutation (Lys58 to Glu) enhanced B2M-MHC heavy chain interactions but reduced CD8alphaalpha binding.
  • This mutation acted as a potent antagonist of CTL activation.

Conclusions:

  • Beta(2)-microglobulin plays a crucial, though previously underestimated, role in CD8alphaalpha binding and CTL function.
  • Targeting specific residues in B2M can modulate CTL responses.
  • These findings suggest a novel therapeutic strategy for CTL-specific immunosuppression.